JPMorgan lowered the firm’s price target on Viking Therapeutics (VKTX) to $75 from $80 and keeps an Overweight rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics Navigates Regulatory Risks Amid U.S. Policy Shifts
- Viking Therapeutics’ Earnings Call: Clinical Success Amid Financial Challenges
- Viking Therapeutics price target raised to $102 from $98 at Morgan Stanley
- Promising Clinical Progress and Accelerated Enrollment Drive Buy Rating for Viking Therapeutics
- Viking Therapeutics offered ‘transformative’ Q3 update, says Cantor Fitzgerald